

Phone: 800.511.	.5144 • Fax: 877.541.1503
Date Shipment Needed:	Ship To: ☐ Patient ☐ Prescriber
□ Nursing needed; □ Training needed ► All the supplies including syring	ges and needles will be dispensed if needed.

XIFAXAN REFERRAL FORM

DATIENT INCODINGEION			AIFAAAN KE	FERRAL FURIN						
PATIENT INFORMATION			DOD 0 -W-5-00					10/		
Patient Name:			DOB: Sex: □M □F □Othe		er:		Weight:	□lbs.	□ kg.	
SSN:	Phone:		Allergies:							
Address:				City:		State:		Zip:		
Emergency Contact:			Phone:			\square Additional	Informat	ion Attached		
PRESCRIBER INFORMATION										
Prescriber:			NPI:		DEA:		State Lic:			
Supervising Physician:				Practice Name:		<u>'</u>				
Address:				City:		State:		Zip:		
Phone:	Fax:			Key Office Contact:	:			Phone:		
DIAGNOSIS INFORMATION / ME		FNT		Tries						
Primary Diagnosis: ☐ K58.0 Irrital Has patient been treated previously	ble Bowel Syndrome	with Diarrhea					E. coli 🗆	Other:		
	·						Г	Datas / Start / En	٩/	
Irritable Bowel Syndrome with ☐ Antispasmodic:	Diarrnea	Dates (Start /	Ena)	Hepatic Encephal			L	Dates (Start / En	u)	_
				☐ Ciprofloxacin☐ Lactulose			-			
☐ Dicyclomine (Bentyl)				☐ Lactulose			-			
☐ Hyosyamine (Levsin)					e					
☐ Cimetropium				□ Neomycin						
☐ Diphenoxylate / Atropine (L	_omotii)			☐ Other:						
☐ Loperaminde (Imodium)										
□ Lotronex (Alosetron)										_
☐ Tricyclic Antidepressants										_
☐ Amitriptyline										_
Other:										_
☐ OTC Medications										_
☐ Fiber Supplements										_
☐ Anti-diarrheal										
■ Is patient <i>currently</i> on therapy?	☐ Yes ☐ No Medic	ation(s):								
• Will patient stop taking the above n	nedication(s) before s	tarting the new n	nedication?	es No If yes:						
- How long should patient wait before	e starting the new me	dication?		•						
 Other medication(s) patient is curre 			with dosage and	direction (or fax medica	ation profile	۵).				
outer medication(o) patient to carre	may taking molaanig		, with accorded and	anoction (or lax modice	ation promi	o)				
 Patient's medical history includes: 	□ Covera hanatia	impoirment 🗆	Current program	/ Other:						
	□ Severe-nepatic	ітірантіені 🗆	Current pregnancy	/ Liother						
INSURANCE INFORMATION										
□ Please attach front and back of	of patient's insura	ince card (med	dical and presc	ription)						
COPAY CARD ENROLLMENT										
□ Please check if enrolling in co	pay card C	opay ID:								
PRESCRIPTION INFORMATION										
☐ Xifaxan® 550 mg Tablet	Sambaa, 1 tablat DO th		. 11				OTV:	40 Tablata	I Daglla.	
 ☐ Irritable Bowel Syndrome with D ☐ Hepatic Encephalopathy: 1 tal 		,	r 14 days ^if recurrer	nce occurs then patient can be	e retreated w	ith the same regimen	QTY: _		Refills:	
	biet PO two times a t	ay					QII		Refills:	
☐ Xifaxan® 200 mg Tablet	oli: 1 tablet DO three	times daily for 3	dave				QTY:	9 Tablets	Refills:	
☐ Traveler's diarrhea due to E. coli: 1 tablet PO three times daily for 3 days				QII	3 Tablets	Neillis.				
☐ Other:							QTY: _		Refills:	
				f						
authorize AcariaHealth to enroll me in a manufacture manufacturer the minimum necessary information about								•		
nformation regarding therapies. I understand that I m										
not affect my ability to obtain treatment from the pharm	•		-				,	-	,	
Patient Signature:		Nate:								
anont Olynature.		Dalo								
Prescriber's Signature:				_		spense as Written	١	Date:		
Prescriber s Signature Prescriber certifies that this referral form co	ntains an original signa	ure and is signed h	v the treating prescr		,	•	,		tronic prescripti	on or on
official state prescription blank. In the even								, , , , , , , , , , , , , , , , , , , ,		
MDODTANT NOTICE: This								F - 4 - 7 4	Di	

IMPORTANT NOTICE: This message may contain privileged and confidential information and is intended only for the individual named. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document by mistake, then destroy this document. Please direct all verification or notification to AcariaHealth or any of its subsidiaries using the contact information provided on this coversheet.